Injectable calcium phosphate ceramics prevent osteoclastic differentiation and osteoporotic bone loss: Potential applications for regional osteolysis.
Animals
Bone Diseases, Metabolic
/ drug therapy
Bone Marrow Cells
/ drug effects
Bone Resorption
/ drug therapy
Calcium Phosphates
/ pharmacology
Cell Differentiation
/ drug effects
Cell Line
Ceramics
/ pharmacology
Injections
/ methods
Macrophages
/ drug effects
Mice
Mice, Inbred C57BL
NF-kappa B
/ metabolism
NFATC Transcription Factors
/ metabolism
Osteoclasts
/ drug effects
Osteogenesis
/ drug effects
Osteolysis
/ drug therapy
Osteoporosis
/ drug therapy
RAW 264.7 Cells
Bone regeneration
Calcium phosphates powders
Osteoclast
Osteoinduction
Osteolysis
Journal
Materials science & engineering. C, Materials for biological applications
ISSN: 1873-0191
Titre abrégé: Mater Sci Eng C Mater Biol Appl
Pays: Netherlands
ID NLM: 101484109
Informations de publication
Date de publication:
May 2020
May 2020
Historique:
received:
22
08
2019
revised:
11
01
2020
accepted:
21
01
2020
entrez:
25
3
2020
pubmed:
25
3
2020
medline:
15
12
2020
Statut:
ppublish
Résumé
Calcium phosphates (CaPs) in the form of blocks are typically not satisfied for administration to osteoporotic patients because of their rapid resorption rate in vivo. However, injectable CaP powders have not been investigated for their potential in osteoporotic hosts. Herein, CaPs in the form of nanoparticles was reported can inhibit RANKL-stimulated osteoclastic differentiation (OC) and bone resorption, as evidenced by suppressed TRAP-positive cells, disintegrated F-actin rings and downregulated expression of markers for OC. CaP powders also significantly inhibited nuclear factor-κB (NF-κB) and nuclear factor of activated T-cells, cytoplasmic 1 (NFATc1) activation. Furthermore, injectable CaPs reversed bone loss in a mouse model induced by lipopolysaccharide (LPS) and promoted osteoblastic formation in the absent of pro-osteogenic agents. Therefore, injectable CaPs, especially biphasic calcium phosphate (BCP), could be developed as novel agents for the therapy of osteolysis-related diseases caused by inflammation.
Identifiants
pubmed: 32204116
pii: S0928-4931(19)33064-4
doi: 10.1016/j.msec.2020.110691
pii:
doi:
Substances chimiques
Calcium Phosphates
0
NF-kappa B
0
NFATC Transcription Factors
0
calcium phosphate
97Z1WI3NDX
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
110691Informations de copyright
Copyright © 2020. Published by Elsevier B.V.
Déclaration de conflit d'intérêts
Declaration of competing interest The authors declare no conflict of interests.